Cargando…
Cost assessment in melanoma clinical trials: A cross-sectional study
Autores principales: | Goodman, Rachel S., Garner, Desmond C., Koester, Stefan, Patrinely, J. Randall, Dewan, Anna K., Johnson, Douglas B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319333/ https://www.ncbi.nlm.nih.gov/pubmed/37409320 http://dx.doi.org/10.1016/j.jdin.2023.05.005 |
Ejemplares similares
-
Pandemic medicine: the management of advanced melanoma during COVID-19
por: Patrinely, James R, et al.
Publicado: (2020) -
COVID-19: the Emerging Role of Medical Student Involvement
por: Patrinely, James Randall, et al.
Publicado: (2020) -
Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-Risk Resected Melanoma
por: Goodman, Rachel S., et al.
Publicado: (2023) -
Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders
por: Brown, Lauren J, et al.
Publicado: (2021) -
COVID-19 booster vaccination has not decreased access for low-income countries
por: Kalmar, C.L., et al.
Publicado: (2022)